IDH2 and systemic primary carnitine deficiency disease: Our results demonstrate that, in IDH mutant gliomas, (1) the TCA cycle is inhibited, (2) β-oxidation is suppressed, especially in clinical samples due to carnitine deficiency, (3) energy production is reduced, and (4) molecules required for cell division (amino acids and nucleic acids) are reduced.